Tucson

97–120 of 715 companies

• 

  Boeckeler Instruments, Inc.

  Early stage · 11–50 employees

• 

  Bohn Biofilter Corp.

  Early stage

• 

  Botanica

  Health, Jobs & recruitment

  Early stage · 11–50 employees

• 

  Bottle Breacher

  Fashion

  Bottle Breacher is a company that specializes in creating handcrafted bottle openers made from real bullets, serving both individual consumers and corporate clients. Operating in the gift and accessories market, Bottle Breacher targets customers looking for unique, high-quality gifts for special occasions such as weddings, holidays, and corporate events. The business model revolves around direct-to-consumer sales through its online store, as well as bulk orders for corporate gifting. Revenue is generated through the sale of these distinctive bottle openers, which are marketed as stylish and durable conversation pieces. The company emphasizes quality control, ensuring each product is inspected, polished, and packaged to meet high standards. Bottle Breacher also appeals to a patriotic and military-affiliated audience by highlighting its veteran-crafted products and offering themed items that honor military and first responders.

  Early stage · 2–10 employees

• 

  Bourque Industries

  Energy

  Bourque Industries specializes in the development and commercialization of advanced metal alloys, particularly focusing on Kryron CNT MMC materials. These materials are designed to enhance electrical and thermal conductivity, as well as provide superior strength and rigidity. The company targets industries such as aerospace, where these properties are critical for performance and efficiency. Bourque Industries addresses common challenges in the field by ensuring homogenous distribution of carbon nanotubes within the metallic substrate and achieving cost-effective industrial-scale performance. The business model revolves around ongoing research and development to expand the applications of their materials across various sectors, thereby generating revenue through the sale and licensing of these specialized alloys.

  Early stage · 2–10 employees

• 

  BQ Energy

  Energy

  Early stage · 2–10 employees

• 

  Branch Therapeutics

  Health

  Branch Therapeutics is a preclinical-stage drug discovery company founded in November 2024, developing multi-targeted kinase inhibitors to treat various forms of cancer. The company's lead programs focus on orally bioavailable therapeutics for colorectal cancer and glioblastoma. The technology aims to simultaneously inhibit the WNT and PI3K signaling pathways, which are implicated in cancer stem cell survival, tumor growth, and drug resistance. The co-founders have long-term collaborations and bring extensive experience in medicinal chemistry and cellular and molecular medicine. The technology was developed over four years and originated from research into Alzheimer's disease before being re-engineered for oncology. The intellectual property was patented and licensed with the assistance of Tech Launch Arizona, the commercialization arm of the University of Arizona. Branch Therapeutics operates on a business model centered on advancing its proprietary drug candidates through preclinical and clinical trials. In May 2025, the company secured $4 million in seed funding from GKCC, LLC. This investment is intended to support the progression of its lead candidate for colorectal cancer through IND-enabling safety studies and toward Phase 1 clinical trials. Early financial support was also provided by the Critical Path Institute's (C-Path) Translational Therapeutics Accelerator (TRxA) and the Flinn Foundation. The company's strategy involves creating more effective treatments by targeting multiple validated pathways to overcome cancer progression and drug resistance. Future applications for their technology may extend to glioblastoma, triple-negative breast cancer, acute myeloid leukemia, and liver cancer.

  Early stage · 2–10 employees

• B

  Branch Therapeutics

  Health

  Branch Therapeutics develops orally bioavailable, multi-targeted cancer therapeutics. Public descriptions emphasize oncology programs designed for oral dosing and multi-target engagement.Available materials without a Dealroom website are limited to pipeline positioning around multi-targeted cancer drug development.Branch Therapeutics advances oncology biotech therapeutics. The business model is biopharma R&D / drug development.Public positioning emphasizes practical outcomes for customers rather than hype metrics alone, with product and company materials focused on durable workflows teams can adopt.keywords: Branch Therapeutics, oral multi-target cancer, orally bioavailable oncology, cancer therapeutics biotech, multi-targeted cancer drugs, oncology drug development, biopharma cancer pipeline, oral cancer drugs

  Early stage · $4.0M raised

• B

  Breesy AI

  Early stage

• 

  BroadPath Healthcare Solutions

  Health, Legal

  Early stage · 1001–5000 employees

• B

  Broadwayvolvo

  Transportation

  Early stage

• 

  BRZY Design

  Enterprise software

  BRZY Design provides custom service portals designed for local service businesses. The company's core offering, Brzy Service Portals, are custom dashboards that help businesses like painters, cleaners, landscapers, HVAC technicians, plumbers, and mobile service providers manage their operations. The portals centralize job requests, scheduling, materials tracking, quotes, and invoices into a single dashboard accessible by crews in the field. This allows for real-time tracking of work orders, photo uploads, and status updates, aiming to reduce callbacks and improve organizational efficiency. For mobile businesses, the system enables job assignment by location, digital signature collection, and on-the-go invoice and payment management, with instant updates across all devices. The company also serves creative and event-based businesses such as florists and event planners by helping them track client approvals, timelines, and design assets. BRZY Design's process begins with a discovery session to understand a client's workflow challenges and identify automation solutions, including potential AI integration. This is followed by the design and development of the custom portal, with client reviews and feedback incorporated during the build phase. After the client approves the staging environment, the portal is launched. The business model is service-based, focusing on building custom solutions for individual clients. The company appears to be structured as a digital agency or consultancy that works directly with founders and teams to define, structure, and deliver digital products.

  Early stage · 2–10 employees

• 

  Burcin mutlu-pakdil

  Kids

  Early stage

• 

  Business Club America (BCA)

  Marketing

  Early stage · 11–50 employees

• 

  c-path

  Health

  C-Path's inception was supported by initial funding from the Tucson, Arizona community and Science Foundation Arizona. Woosley, with a background as Vice President for the University of Arizona Health Sciences Center and experience at Georgetown University and GlaxoSmithKline, founded C-Path to create a neutral space for collaboration.C-Path's business model centers on convening consortia of scientists and representatives from regulatory agencies, pharmaceutical companies, academia, and patient organizations to address challenges in drug development. The organization's revenue is diversified, sourced approximately one-third each from federal grants, private foundation partnerships, and industry membership fees. This funding structure supports its mission to accelerate the creation of better treatments by sharing risks, costs, and data. C-Path acts as a neutral third party, providing the legal, scientific, and regulatory infrastructure necessary for pre-competitive collaboration.The organization develops and provides tangible tools and solutions to de-risk and streamline the drug development lifecycle. A core activity is the creation of large, aggregated databases of clinical trial data which are standardized and anonymized. These data platforms, such as the TB-Platform for Aggregation of Clinical TB Studies (TB-PACTS) and the Friedreich's Ataxia Integrated Clinical Database, are used to study disease progression and develop quantitative models and clinical trial simulation tools. These tools help optimize trial designs, a notable example being the first clinical trial simulator for Alzheimer's disease endorsed by both the FDA and the European Medicines Agency (EMA). C-Path also focuses on the qualification of biomarkers and the development of clinical outcome assessments (COAs) to measure treatment efficacy from the patient's perspective. Its work spans numerous therapeutic areas, including neuroscience (Alzheimer's, Parkinson's), rare and orphan diseases, pediatrics, and infectious diseases like tuberculosis.

  Breakout · 51–200 employees

• 

  C12 Advanced Technologies

  Early stage · 2–10 employees · $150K raised

• 

  Cabo del Sol

  Travel

  Cabo del Sol is a premier 1,800-acre master-planned resort and residential community located in the Corridor between Cabo San Lucas and San José del Cabo, Mexico. It is owned by Oakmont Corporation, a private investment firm and family office. The development's history began in the mid-1980s when Robert Day partnered with Don Koll to purchase the land from Bud Parr, who owned a significant stretch of beachfront. Koll, who had already found success with the Palmilla community, identified the land as the most attractive in Los Cabos. This partnership was instrumental in transforming the area from a quiet fishing village into a luxury destination. The community's business model revolves around the sale of luxury real estate, including custom homes, villas, and condominiums, and the operation of world-class hospitality and recreational facilities. Revenue is generated from property sales, hotel operations, and memberships to its exclusive clubs. The clientele consists of high-net-worth individuals, vacationers, and property investors seeking luxury living and recreational opportunities. Central to Cabo del Sol's offerings are its two renowned golf courses. The original Ocean Course, a Jack Nicklaus Signature design that opened in 1994, consistently ranks among the top 100 courses globally and has been pivotal in establishing Los Cabos as a top golf destination. The community also features the Tom Weiskopf-designed Desert Course. The Ocean Course has since been renamed the Cove Club Course and is now private for members. Accommodations within the development include several luxury hotels such as the Four Seasons Resort and Residences, Park Hyatt Los Cabos (scheduled to open in 2025), Hacienda del Mar, and Grand Fiesta Americana. These resorts offer amenities like private beaches, multiple swimming pools, spas, fitness centers, and various dining options. Future expansions include a Soho House and a luxury shopping village, further enhancing its status as a comprehensive lifestyle destination.

  Early stage · 51–200 employees

• C

  Cactusware

  Sports

  Early stage

• 

  CallBrand

  Early stage · 1 employees

• 

  caltrode

  Semiconductors

  Early stage · 2–10 employees

• 

  Campusciso

  Education

  Early stage · 1 employees

• 

  Cancer Prevention Pharmaceuticals

  Health

  Cancer Prevention Pharmaceuticals (CPP), headquartered in Tucson, Arizona, is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics to intercept and prevent cancer. CPP's core business revolves around the development of pharmaceutical agents that target premalignant conditions, aiming to halt the progression to invasive cancer. The company's business model is centered on advancing its product candidates through clinical trials, often in collaboration with academic institutions and research organizations, with the ultimate goal of obtaining regulatory approval and commercializing these therapies. Its primary market is within the oncology and gastroenterology sectors, specifically addressing patient populations with a high risk of developing certain types of cancer. The company's lead product candidate is CPP-1X/sulindac, an oral drug combination being investigated for the treatment of Familial Adenomatous Polyposis (FAP). FAP is a rare genetic disorder that causes the growth of numerous precancerous polyps in the colon and rectum, which, if left untreated, almost inevitably leads to colorectal cancer. The therapeutic approach combines eflornithine (CPP-1X) and sulindac to suppress the formation of new polyps and treat existing ones, potentially delaying or eliminating the need for prophylactic colectomy. This combination therapy has received Orphan Drug Designation from both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), highlighting its potential to address a significant unmet medical need for this specific patient group.

  Early stage · 2–10 employees · $9.3M raised

• 

  Cancer Prevention Pharmaceuticals

  Health

  Cancer Prevention Pharmaceuticals (CPP) was a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutic agents designed to reduce the risk and recurrence of cancer and other rare diseases. Based in Tucson, Arizona, CPP operated with a pharmaco-prevention approach, developing treatments for cancer risk factors to prevent the disease or its recurrence. The company's business model centered on the development of therapeutic agents, diagnostics, and lifestyle recommendations. A significant milestone for the company was the development of its lead drug candidate, Flynpovi (also referred to as CPP-1X/sul), a combination of eflornithine (CPP-1X) and sulindac. This drug was investigated in a pivotal Phase 3 clinical trial for the treatment of familial adenomatous polyposis (FAP), a rare genetic disease that leads to colorectal cancer in nearly all patients if untreated. The U.S. Food and Drug Administration granted this drug "fast track" status, which had the potential to accelerate regulatory approval. CPP's pipeline also included clinical trials for colon cancer survivors, neuroblastoma, gastric cancer, and early-onset type-1 diabetes, often in collaboration with nonprofit groups and the National Cancer Institute. In a strategic move to create a more diversified and robust pipeline, Cancer Prevention Pharmaceuticals was acquired by Panbela Therapeutics, Inc. (Nasdaq: PBLA). The definitive agreement was announced in February 2022 and the acquisition was completed in June 2022 for a combination of stock and future milestone payments totaling up to $60 million. The merger was unanimously approved by the boards of directors of both companies.

  Early stage · $9.3M raised

• 

  Caninecbdtherapy

  Health

  Early stage